Answers are grounded in this paper and cite their sources.
Anti-VEGF treatment was associated with preserved useful visual acuity in almost 20% of patients over their average remaining lifetime. More than 80% of patients will cease treatment over that time, having likely experienced a deterioration of vision beforehand. This is a remarkable outcome compared with outcomes without intervention, which lead to legal blindness within 3 years of disease onset in 80% of those affected. These findings underline the public health necessity of providing anti-VEGF treatment to persons in need.
No takes yet. Share an insight, caveat, or question.
Finger et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: